BPC-157 vs Glepaglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Body Protection Compound-157, Pentadecapeptide BPC 157
BPC-157 is a synthetic 15-amino-acid peptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) based on a fragment of a protective protein found in human gastric juice. It is studied almost entirely in animals for tendon, ligament, gut, and tissue healing, and it has racked up hundreds of preclinical papers. The catch: it is not approved by any regulator for any use, and the human evidence is a handful of small pilot studies, not real clinical proof.
Also: ZP1848, Zeydovio
Glepaglutide is Zealand Pharma's long-acting GLP-2 analog for short bowel syndrome, built to be injected once or twice a week instead of daily like teduglutide. Its path has been bumpy. The FDA rejected it in December 2024 because the single phase 3 trial only worked at the twice-weekly dose, but Europe went the other way: in September 2026 the EMA's CHMP recommended approval under the name Zeydovio. As of late October 2026 the final European Commission decision is still pending, and the US needs another trial.
Key Comparison Insights
- Both peptides belong to the Healing category, suggesting similar primary applications.
- Glepaglutide has stronger research evidence (Human Trials) compared to BPC-157 (Animal Studies).
Detailed Comparison
| Attribute | BPC-157 | Glepaglutide |
|---|---|---|
| Category | Healing | Healing |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The leading hypothesis is that BPC-157 promotes new blood vessel growth by upregulating the VEGFR2 receptor, the same receptor that drives angiogenesis, and by tapping into the nitric oxide system through the Akt-eNOS pathway. Better blood supply to injured tissue would, in theory, speed healing of tendons, muscle, and gut lining. Animal work also points to anti-inflammatory effects and interaction with growth-factor signaling. It is worth being blunt here: these mechanisms are mostly worked out in rodents, and the exact molecular target of BPC-157 has never been definitively pinned down. Treat the pathway story as a well-supported hypothesis, not settled fact. | Glepaglutide activates the GLP-2 receptor in the intestine, the same target as teduglutide, which makes the gut lining grow and absorb more fluid and nutrients. What is different is the delivery. After a subcutaneous injection it forms a depot and is slowly released, mostly as two active metabolites rather than the parent molecule. In a healthy-volunteer study the effective half-life was roughly 88 to 124 hours, long enough to make weekly or twice-weekly dosing plausible. The flip side is the same as the rest of the GLP-2 class: anything that makes gut tissue grow raises questions about polyps and tumors over the long run. |
| Common Dosing | 250-500 mcg twice daily 1-2x daily | 10 mg twice weekly (trial dose) Twice weekly |
| Administration | Subcutaneous injection near injury site, or systemic | Subcutaneous injection (prefilled pen in the EU filing) |
| Typical Duration | 4-12 weeks in most research protocols | 24 weeks in EASE-1, with longer-term extension studies |
| Best Time to Take | Morning and evening (or near injury site timing) | Same days each week (trial schedule) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The preclinical record is genuinely large. A 2025 narrative review in the journal Biomedicines counted hundreds of published animal studies showing BPC-157 accelerating healing across tendon, muscle, bone, gut, liver, and nervous-system injury models. The problem is the human side is nearly empty. That same review found only three published human pilot studies (knee pain injections, bladder injections for interstitial cystitis, and an intravenous safety trial) and concluded BPC-157 should be treated as investigational and not recommended for clinical use until proper trials exist. Pharmacokinetic work in rats and dogs found a very short elimination half-life (under 30 minutes after injection) and rapid breakdown into amino acid fragments, which raises real questions about how oral capsules sold online could deliver an intact peptide. Bottom line: lots of promising animal data, no completed randomized controlled trials in people, and no regulatory approval anywhere. | The main evidence is EASE-1, published in Gastroenterology in April 2025 (Jeppesen and colleagues). It randomized 106 adults with SBS and intestinal failure to glepaglutide 10 mg twice weekly, 10 mg once weekly, or placebo for 24 weeks. Twice weekly cut weekly parenteral support by 5.13 L versus 2.85 L on placebo (p=0.0039), and 65.7% were responders versus 38.9% on placebo. Once weekly (3.13 L) did not reach significance. A handful of patients came off IV support completely, none on placebo. On 19 December 2024 the FDA issued a complete response letter saying there was not enough evidence at the to-be-marketed dose and asked for another trial; Zealand is running EASE-5 to support a US resubmission. Zealand filed in Europe in June 2025 and the CHMP gave a positive opinion on 17 September 2026 for adults with SBS (10 mg prefilled pen). Common side effects listed by the EMA are injection site reactions, abdominal pain, nausea, and vomiting. Bottom line: real phase 3 data, but from a single trial with one of two doses positive, which is exactly why the two regulators disagreed. |
Frequently Asked Questions: BPC-157 vs Glepaglutide
What is the difference between BPC-157 and Glepaglutide?
BPC-157 is a healing peptide that bpc-157 is a synthetic 15-amino-acid peptide (sequence gly-glu-pro-pro-pro-gly-lys-pro-ala-asp-asp-ala-gly-leu-val) based on a fragment of a protective protein found in human gastric juice. it is studied almost entirely in animals for tendon, ligament, gut, and tissue healing, and it has racked up hundreds of preclinical papers. the catch: it is not approved by any regulator for any use, and the human evidence is a handful of small pilot studies, not real clinical proof. Glepaglutide is a healing peptide that glepaglutide is zealand pharma's long-acting glp-2 analog for short bowel syndrome, built to be injected once or twice a week instead of daily like teduglutide. its path has been bumpy. the fda rejected it in december 2024 because the single phase 3 trial only worked at the twice-weekly dose, but europe went the other way: in september 2026 the ema's chmp recommended approval under the name zeydovio. as of late october 2026 the final european commission decision is still pending, and the us needs another trial. The main differences lie in their mechanisms of action and clinical applications.
Which is better, BPC-157 or Glepaglutide?
Neither is universally "better" - the choice depends on your specific goals. BPC-157 is typically used for healing purposes, while Glepaglutide is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can BPC-157 and Glepaglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using BPC-157 and Glepaglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.